Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non–small cell lung cancer and melanoma brain metastases
Jack M. Qian(South Shore Hospital), Ayal A. Aizer(Brigham and Women's Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Allison Martin(Albert Einstein College of Medicine), Daniel Cagney(Mater Misericordiae University Hospital), Paul J. Catalano(Computational Physics (United States)), F. Stephen Hodi(Harvard University), Lubna Hammoudeh(Harvard University), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), Kate Martin(Harvard University)
Cited by 33
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k